Evidence map›Paper›PMID 41769280›Full record

ArticleArchives of Razi Institute2025

Screening and Docking Molecular Studies of Natural Products Targeting overexpressed Receptors HER-2 in Breast Cancer.

Lenchi Nesrine, Maouche Naima, Khemili-Talbi Souad

Abstract read
In one paragraph

Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lenchi NesrineDepartment of Natural and Life Sciences, Faculty of Sciences, University Algiers 1 BenYoucef Benkhedda, Algiers, Algeria.
Maouche NaimaDepartment of Natural and Life Sciences, Faculty of Sciences, University Algiers 1 BenYoucef Benkhedda, Algiers, Algeria.
Khemili-Talbi SouadDepartment of Microbiology and Biomolecules, Faculty of Sciences, University of M'Hamed Bougara of Boumerdès. Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the first cancer to affect a community. Because of its extremely high mitotic activity, breast cancer that tests positive for HER 2 is considered to have a poor prognosis. Due to the side effects of chemical drugs, patients are increasingly turning to natural medicine, such as phytotherapy and nutritherapy. The study uses a bioinformatics approach (molecular docking) to searchfor new, non-toxic anti-cancer inhibitors. The studyscreens 102 ligands from natural and dietary compounds that are likely to interact with the HER-2. The virtual screening results of the allow us to select the 23 best compounds which can be proposed as the most effective HER-2 inhibitors. Lycopene would be a very promising ligand which presents a DeltaG of -9.82 kcal/mol. Other promising ligands include beta-carotene (DeltaG of -8.58), P-cumaric acid kcal/mol (DeltaG of -8.57) and Curcumin (DeltaG of -8.46). Other compounds, luteolin, anacardium (Anacardic acid) ,and alpha-Tocopherol, were found to have the strongest inhibitory effects with DeltaG values of -7.92 kcal/mol, -7.89 kcal/mol, and-7.85 kcal/mol, respectively. These compounds act directly on residues keys found in the hydrophobic pocket II (ATP binding site) and the hydrophobic region (the αC-β4 loop) of the EGFR domain. Pinoresinol, Kaempferol and Caffeic acid have DeltaGs of -7.48 Kcal/mol, -6.88 Kcal/mol and -6.34 kcal/mol, respectively. These three ligands are specific to the conserved regions of the HER-2 receptor and interact with the C-terminal, the C-lobe activation loop and the N-lobe P loop of the tyrosine kinase domain, respectively. Lapatinib (chemical compound) and quercetin (natural compound) have DeltaG of -7.58 kcal/mol and -7.28 kcal/mol, respectively, form a hydrogen bond with the same residue in the hydrophobic region. All the natural molecules seem very promising and, after

Indexed as

Antineoplastic AgentsBiological ProductsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMolecular Docking SimulationAntineoplastic AgentsBiological ProductsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBrest CancerHER-2Molecular DockingNatural Compounds

Identifiers

PMID41769280
PMCPMC12936590

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.